García-Casares Natalia, García-Arnés Juan Antonio, Gómez-Huelgas Ricardo, Valdivielso-Felices Pedro, García-Arias Carlota, González-Santos Pedro
Departamento de Medicina; Facultad de Medicina; Universidad de Málaga; Centro de Investigaciones Médico-Sanitarias, CIMES.
Unidad de Gestión Clínica de Endocrinología.
Rev Neurol. 2014 Dec 1;59(11):517-24.
The glucagon-like peptide-1 (GLP-1) mimetics are an established therapeutic option for patients with type 2 diabetes. However, the properties of the GLP-1 mimetics go beyond the strict metabolic control of the patients with diabetes. The neuroprotective effects of GLP-1 have been shown in recent studies opening new areas of research in neurodegenerative diseases such as Alzheimer's disease (AD), among others. AIM. Systematic review including experimental studies and human clinical trials demonstrating the neuroprotective properties of GLP-1 mimetics in AD.
The experimental studies that have been conducted in rodent models of AD have demonstrated the neuroprotective properties of GLP-1 in the central nervous system reducing beta-amyloid plaques, the oxidative stress and the inflammatory brain response. Clinical trials in patients with cognitive impairment and AD testing the effects of GLP-1 analogs have recently started.
The GLP-1 analogs have neuroprotective properties. Considering that type 2 diabetes is a risk factor for cognitive impairment and dementia, the benefits of GLP-1 mimetics on cognition must be considered. Likewise, the GLP-1 mimetics represent a promising treatment for neurodegenerative diseases such as AD.
胰高血糖素样肽-1（GLP-1）类似物是2型糖尿病患者已确立的治疗选择。然而，GLP-1类似物的特性超出了对糖尿病患者严格的代谢控制范围。近期研究显示GLP-1具有神经保护作用，这为诸如阿尔茨海默病（AD）等神经退行性疾病开辟了新的研究领域。目的：进行系统综述，纳入证明GLP-1类似物在AD中具有神经保护特性的实验研究和人体临床试验。
在AD啮齿动物模型中开展的实验研究已证明GLP-1在中枢神经系统具有神经保护特性，可减少β-淀粉样蛋白斑块、氧化应激和脑部炎症反应。近期已启动针对认知障碍和AD患者测试GLP-1类似物效果的临床试验。
GLP-1类似物具有神经保护特性。鉴于2型糖尿病是认知障碍和痴呆的一个危险因素，必须考虑GLP-1类似物对认知的益处。同样，GLP-1类似物是AD等神经退行性疾病一种有前景的治疗方法。
